Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSwisher, Elizabeth M.
dc.contributor.authorKwan, Tanya T.
dc.contributor.authorOza, Amit M.
dc.contributor.authorTinker, Anna V.
dc.contributor.authorRay-Coquard, Isabelle
dc.contributor.authorOaknin benzaquen, Ana Mazaltob
dc.date.accessioned2022-01-20T14:13:30Z
dc.date.available2022-01-20T14:13:30Z
dc.date.issued2021-05-03
dc.identifier.citationSwisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021 May 3;12:2487.
dc.identifier.issn2041-1723
dc.identifier.urihttp://hdl.handle.net/11351/6853
dc.descriptionOvarian cancer; Tumour biomarkers
dc.description.abstractARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesNature Communications;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectOvaris - Càncer - Tractament
dc.subjectOvaris - Càncer - Recaiguda
dc.subject.meshOvarian Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshNeoplasm Recurrence, Local
dc.titleMolecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41467-021-22582-6
dc.subject.decsneoplasias ováricas
dc.subject.decs/farmacoterapia
dc.subject.decsrecurrencia neoplásica local
dc.relation.publishversionhttps://doi.org/10.1038/s41467-021-22582-6
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Swisher EM] University of Washington, Seattle, WA, USA. [Kwan TT] Clovis Oncology, Inc., Boulder, CO, USA. [Oza AM] Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. [Tinker AV] BC Cancer—Vancouver, Vancouver, BC, Canada. [Ray-Coquard I] GINECO, Centre Léon Bérard and University Claude Bernard, Lyon, France. [Oaknin A] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid33941784
dc.identifier.wos000656508100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record